Live tape
Top 8, mentions 7d997GOOGL178 mentions▲ +0.05NVDA167 mentions▲ +0.10SPY149 mentions▲ +0.05QQQ120 mentions▲ +0.08META117 mentions▲ +0.05TSLA91 mentions▲ +0.06AMZN90 mentions▲ +0.04MSFT85 mentions▲ +0.07

Equity · Healthcare

HUM

Humana Inc. · NYSE

$387 +2.11% 1D Finazon · prior-day close · Aug 24, 2026
Price · Chart
Our own end-of-day closes 44 sessions
$420 $340 23 Jun 24 Aug

The line runs $359 on 23 June through $387 on 24 August, on a scale from $340 to $420. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView

The chart above plots the price of HUM over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 44 sessions over that window: $359 on 23 June 2026 through $387 on 24 August 2026.

Market cap $46.5B
P/E (TTM) 14.7
52-week range $164 – $410
Avg volume 244.5K

Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Sep 21, 2026

HUM insider trades

SEC Form 4 · last 90 days · newest Form 4 filing 1 Sep 2026
Open-market buys 0
Open-market sells 0
Non-trade filings 3

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
01 Sep 2026 Nundy Shantanu Chief Medical Officer Award 2,549
01 Aug 2026 Crawford Frederick John Director Award 544
01 Aug 2026 Smith Paul John Director Award 544

HUM reported financials

SEC EDGAR XBRL

HUM reported revenue of $5.8B for the fiscal year ended 31 Dec 2025. Net income over the same period was $1.2B.

Figure Reported Period
Revenue $5.8B 31 Dec 2025 fiscal year
Net income $1.2B 31 Dec 2025 fiscal year
Diluted EPS $9.84 31 Dec 2025 fiscal year
Total assets $55.3B 31 Mar 2026 at period end
Total equity $18.6B 31 Mar 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 31 Mar 2026

HUM earnings

SEC EDGAR
Date Period EPS Revenue
31 Mar 2026 Q1 2026 $9.83 $39.65B
31 Dec 2025 FY 2025 $9.84 $129.66B
30 Sep 2025 Q3 2025 $1.62 $32.65B
30 Jun 2025 Q2 2025 $4.51 $32.39B
31 Mar 2025 Q1 2025 $10.30 $32.11B
31 Dec 2024 FY 2024 $9.98 $117.76B
30 Sep 2024 Q3 2024 $3.98 $29.40B
30 Jun 2024 Q2 2024 $5.62 $29.54B

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

HUM institutional holders

SEC Form 13F

14 of the 45 institutional funds we track reported a HUM position for the quarter ended 30 Jun 2026 — a combined $980.3M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Marshall Wace New position 545,978 $216.9M
Citadel Advisors Added +217.0% shares 449,022 $178.4M
Millennium Management Added +213.2% shares 352,698 $140.1M
Glenview Capital Management Held (±25%) −24.1% shares 254,216 $101.0M
Balyasny Asset Management Added +316.1% shares 221,454 $88.0M
AQR Capital Management Held (±25%) +15.5% shares 222,408 $86.8M
D. E. Shaw & Co. Trimmed −63.2% shares 204,543 $81.2M
Point72 Asset Management New position 98,491 $39.1M
Tudor Investment Corp Added +71.3% shares 37,563 $14.9M
Man Group Trimmed −79.1% shares 33,467 $13.3M

Showing the 10 largest of 14 reported positions. The figures above count all of them.

Source: SEC EDGAR 13F filings

HUM fails-to-deliver

SEC CNS data

On 28 Aug 2026, 451 shares of HUM failed to deliver (about $177K).

Settlement date Shares failed Notional % of shares out
28 Aug 2026 451 $177K <0.001%
25 Aug 2026 44 $17K <0.001%
24 Aug 2026 271 $103K <0.001%
10 Aug 2026 1,000 $385K 0.001%

Source: SEC fails-to-deliver (CNS) data

Congressional trades in HUM

STOCK Act disclosures

The most recent congressional trade disclosed in HUM is a sale by Julia Letlow (house, LA), dated 10 Feb 2026.

Date Member Type Amount
10 Feb 2026 filed 12 Mar 2026 Julia Letlow house · Republican–LA Sale $1K–$15K

Source: U.S. House of Representatives financial disclosures